Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

Clinical trial NCT07281833 · RECRUITING

Trial details

NCT number: NCT07281833
Sponsor: Women's Cancer Study Group GmbH
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancer HR-positive Breast Cancer Advanced Breast Cancer Metastatic Breast Cancer HER2-negative Breast Cancer

Start date: 2025-11-27
Primary completion: 2030-03-01
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.